Jiang S Y, Shi Y K
Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Zhonghua Zhong Liu Za Zhi. 2017 Oct 23;39(10):721-725. doi: 10.3760/cma.j.issn.0253-3766.2017.10.001.
With the extensive application in clinical practice, biological medicine plays a significant role in both treatment and supportive care in oncology. With the expiration of original drug patents, biosimilars emerge. The biosimilars are defined as biological drugs that are be highly similar but not identical to the biological reference. Their development and evaluation procedure are different from those of small molecular chemical generics. Biosimilars are expected to reduce the health care costs worldwide. The booming developments of biosimilars, such as rituximab, trastuzumab and bevacizumab in medical oncology can optimize the clinical strategies, offer patients more treatment options and reduce the medical expenditure. In this article, we review the advances in the field of biosimilars, especially focus on the challenges and opportunities of biosimilars in clinical oncology.
随着生物医药在临床实践中的广泛应用，其在肿瘤学的治疗和支持性护理中都发挥着重要作用。随着原研药物专利的到期，生物类似药应运而生。生物类似药被定义为与生物参照药高度相似但并非完全相同的生物药物。它们的研发和评估程序与小分子化学仿制药不同。生物类似药有望降低全球医疗保健成本。利妥昔单抗、曲妥珠单抗和贝伐单抗等生物类似药在肿瘤医学中的蓬勃发展可以优化临床策略，为患者提供更多治疗选择并降低医疗支出。在本文中，我们综述了生物类似药领域的进展，尤其关注生物类似药在临床肿瘤学中的挑战与机遇。
